Pomerantz LLP Investigates Potential Securities Claims Against Corcept Therapeutics Incorporated
New York, NY – March 17, 2025
Pomerantz LLP, a leading securities law firm, is investigating potential securities claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT).
Background
Corcept Therapeutics is a biopharmaceutical company that focuses on the development and commercialization of drugs for the endocrine system. The Company’s primary product is Korlym, a cortisol synthesis inhibitor indicated for the treatment of hypercortisolism in end-stage renal disease patients with Type 2 diabetes mellitus and hypertension.
Investigation
The investigation concerns whether Corcept and certain of its officers and/or directors have made false and/or misleading statements and/or failed to disclose material information in violation of the Securities Exchange Act of 1934 (the “Exchange Act”).
Specifically, the investigation focuses on whether the Company and its executives made misrepresentations and/or failed to disclose: (i) the true commercial potential of Korlym, (ii) the Company’s financial condition, and (iii) certain related party transactions.
Implications for Investors
If you are a shareholder of Corcept and are interested in learning more about the investigation or your legal rights, please contact Danielle Peyton at [email protected] or 646-581-9980, ext. 168. You can also fill out the contact form on Pomerantz LLP’s website.
World Impact
The investigation against Corcept could have significant implications for the biopharmaceutical industry, particularly for companies with products in the endocrine system space. It could also impact investor confidence in the sector as a whole.
Moreover, the investigation could lead to increased scrutiny of Corcept’s business practices and financial reporting. If the allegations are proven true, it could result in regulatory action, fines, and potential damages for the Company and its shareholders.
Conclusion
Pomerantz LLP is dedicated to protecting investors’ rights, and the investigation into Corcept Therapeutics is no exception. If you are a shareholder of the Company and believe that you have suffered a loss as a result of misrepresentations or non-disclosures, you may be entitled to recover your losses. For more information, please contact Danielle Peyton at [email protected] or 646-581-9980, ext. 168.
As a responsible and informed investor, it is crucial to stay informed about potential securities investigations and their potential impact on your investments. By working with experienced securities lawyers like those at Pomerantz LLP, you can protect your rights and potentially recover your losses. Stay tuned for further updates on this developing story.
- Corcept Therapeutics is under investigation by Pomerantz LLP for potential securities violations.
- The investigation concerns misrepresentations and/or failed disclosures regarding Korlym, financial condition, and related party transactions.
- Investors who suffered losses due to these alleged misrepresentations or non-disclosures may be entitled to recover their losses.
- The investigation could have significant implications for the biopharmaceutical industry and investor confidence in the sector.
